Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome.


Journal

Nature cell biology
ISSN: 1476-4679
Titre abrégé: Nat Cell Biol
Pays: England
ID NLM: 100890575

Informations de publication

Date de publication:
03 2022
Historique:
received: 07 12 2020
accepted: 24 01 2022
entrez: 16 3 2022
pubmed: 17 3 2022
medline: 5 4 2022
Statut: ppublish

Résumé

Transfer RNA-derived fragments (tRFs) are emerging small noncoding RNAs that, although commonly altered in cancer, have poorly defined roles in tumorigenesis

Identifiants

pubmed: 35292784
doi: 10.1038/s41556-022-00852-9
pii: 10.1038/s41556-022-00852-9
pmc: PMC8924001
doi:

Substances chimiques

PAIP1 protein, human 0
Peptide Initiation Factors 0
RNA-Binding Proteins 0
Pseudouridine 1445-07-4
RNA, Transfer 9014-25-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-306

Informations de copyright

© 2022. The Author(s).

Références

Rosace, D., Lopez, J. & Blanco, S. Emerging roles of novel small non-coding regulatory RNAs in immunity and cancer. RNA Biol. 17, 1196–1213 (2020).
Guzzi, N. et al. Pseudouridylation of tRNA-derived fragments steers translational control in stem cells. Cell 173, 1204–1216 (2018).
doi: 10.1016/j.cell.2018.03.008 pubmed: 29628141
Craig, A. W. B., Haghighat, A., Yu, A. T. K. & Sonenberg, N. Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation. Nature 392, 520–523 (1998).
doi: 10.1038/33198 pubmed: 9548260
Pelletier, J., Graff, J., Ruggero, D. & Sonenberg, N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 75, 250–263 (2015).
doi: 10.1158/0008-5472.CAN-14-2789 pubmed: 25593033 pmcid: 4299928
Ge, J. & Yu, Y. T. RNA pseudouridylation: new insights into an old modification. Trends Biochem. Sci. 38, 210–218 (2013).
doi: 10.1016/j.tibs.2013.01.002 pubmed: 23391857 pmcid: 3608706
Behm-Ansmant, I. et al. The Saccharomyces cerevisiae U2 snRNA:pseudouridine-synthase Pus7p is a novel multisite-multisubstrate RNA:Psi-synthase also acting on tRNAs. RNA 9, 1371–1382 (2003).
doi: 10.1261/rna.5520403 pubmed: 14561887 pmcid: 1287059
Schwartz, S. et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell 159, 148–162 (2014).
doi: 10.1016/j.cell.2014.08.028 pubmed: 25219674 pmcid: 4180118
Kahvejian, A., Svitkin, Y. V., Sukarieh, R., M’Boutchou, M. N. & Sonenberg, N. Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Gene Dev. 19, 104–113 (2005).
doi: 10.1101/gad.1262905 pubmed: 15630022 pmcid: 540229
Chalmers, M. J., Busby, S. A., Pascal, B. D., West, G. M. & Griffin, P. R. Differential hydrogen/deuterium exchange mass spectrometry analysis of protein–ligand interactions. Expert Rev. Proteomics 8, 43–59 (2011).
doi: 10.1586/epr.10.109 pubmed: 21329427 pmcid: 3113475
Roy, G. et al. Paip1 interacts with poly(A) binding protein through two independent binding motifs. Mol. Cell. Biol. 22, 3769–3782 (2002).
doi: 10.1128/MCB.22.11.3769-3782.2002 pubmed: 11997512 pmcid: 133836
Khaleghpour, K. et al. Dual interactions of the translational repressor Paip2 with poly(A) binding protein. Mol. Cell. Biol. 21, 5200–5213 (2001).
doi: 10.1128/MCB.21.15.5200-5213.2001 pubmed: 11438674 pmcid: 87244
Khaleghpour, K. et al. Translational repression by a novel partner of human poly(A) binding protein, Paip2. Mol. Cell 7, 205–216 (2001).
doi: 10.1016/S1097-2765(01)00168-X pubmed: 11172725
Tcherkezian, J. et al. Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5′ TOP mRNA translation. Gene Dev. 28, 357–371 (2014).
doi: 10.1101/gad.231407.113 pubmed: 24532714 pmcid: 3937514
Schuster, S. L. & Hsieh, A. C. The untranslated regions of mRNAs in cancer. Trends Cancer 5, 245–262 (2019).
doi: 10.1016/j.trecan.2019.02.011 pubmed: 30961831 pmcid: 6465068
Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M. & Weissman, J. S. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat. Protoc. 7, 1534–1550 (2012).
doi: 10.1038/nprot.2012.086 pubmed: 22836135 pmcid: 3535016
Meyuhas, O. & Kahan, T. The race to decipher the top secrets of TOP mRNAs. Biochim. Biophys. Acta 1849, 801–811 (2015).
doi: 10.1016/j.bbagrm.2014.08.015 pubmed: 25234618
Truitt, M. L. & Ruggero, D. New frontiers in translational control of the cancer genome. Nat. Rev. Cancer 16, 288–304 (2016).
doi: 10.1038/nrc.2016.27 pubmed: 27112207 pmcid: 5491099
Gandin, V. et al. Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature 455, 684–U681 (2008).
doi: 10.1038/nature07267 pubmed: 18784653 pmcid: 2753212
Kirn-Safran, C. B. et al. Global growth deficiencies in mice lacking the ribosomal protein HIP/RPL29. Dev. Dyn. 236, 447–460 (2007).
doi: 10.1002/dvdy.21046 pubmed: 17195189
Valli, R. et al. Different loss of material in recurrent chromosome 20 interstitial deletions in Shwachman–Diamond syndrome and in myeloid neoplasms. Mol. Cytogenet. 6, 56 (2013).
Qi, Y. K. et al. Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome. Sci. Rep. 7, 2323 (2017).
Wu, L. Y. et al. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34
doi: 10.1007/s00277-012-1486-2 pubmed: 22580751
Fonseca, B. D., Lahr, R. M., Damgaard, C. K., Alain, T. & Berman, A. J. LARP1 on TOP of ribosome production. Wiley Interdiscip. Rev. RNA 9, e1480 (2018).
Philippe, L., van den Elzen, A. M. G., Watson, M. J. & Thoreen, C. C. Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5′ TOP motifs. Proc. Natl Acad. Sci. USA 117, 5319–5328 (2020).
doi: 10.1073/pnas.1912864117 pubmed: 32094190 pmcid: 7071917
Cockman, E., Anderson, P. & Ivanov, P. TOP mRNPs: molecular mechanisms and principles of regulation. Biomolecules 10, 969 (2020).
Jerez, A. et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 119, 6109–6117 (2012).
doi: 10.1182/blood-2011-12-397620 pubmed: 22553315 pmcid: 3383019
Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5–19 (2017).
doi: 10.1038/nrc.2016.112 pubmed: 27834397
Malcovati, L. et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122, 2943–2964 (2013).
doi: 10.1182/blood-2013-03-492884 pubmed: 23980065 pmcid: 3811170
Shiozawa, Y. et al. Gene expression and risk of leukemic transformation in myelodysplasia. Blood 130, 2642–2653 (2017).
doi: 10.1182/blood-2017-05-783050 pubmed: 29097382
Guo, Y. et al. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. BMC Genomics 16, 727 (2015).
doi: 10.1186/s12864-015-1929-y pubmed: 26400237 pmcid: 4581457
Stevens, B. M. et al. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nat. Commun. 9, 3694 (2018).
doi: 10.1038/s41467-018-05984-x pubmed: 30209285 pmcid: 6135858
Tohyama, K. et al. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br. J. Haematol. 91, 795–799 (1995).
doi: 10.1111/j.1365-2141.1995.tb05391.x pubmed: 8547120
Signer, R. A., Magee, J. A., Salic, A. & Morrison, S. J. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature 509, 49–54 (2014).
doi: 10.1038/nature13035 pubmed: 24670665 pmcid: 4015626
Dimitriou, M. et al. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Oncotarget 7, 72685–72698 (2016).
doi: 10.18632/oncotarget.12234 pubmed: 27683035 pmcid: 5341937
Chen, J. et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat. Med. 25, 103–110 (2019).
doi: 10.1038/s41591-018-0267-4 pubmed: 30510255
Theocharides, A. P. A., Rongvaux, A., Fritsch, K., Flavell, R. A. & Manz, M. G. Humanized hemato-lymphoid system mice. Haematologica 101, 5–19 (2016).
doi: 10.3324/haematol.2014.115212 pubmed: 26721800 pmcid: 4697887
Goncalves, K. A. et al. Angiogenin promotes hematopoietic regeneration by dichotomously regulating quiescence of stem and progenitor cells. Cell 166, 894–906 (2016).
doi: 10.1016/j.cell.2016.06.042 pubmed: 27518564 pmcid: 4988404
Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013).
pubmed: 23333149 pmcid: 3595363
Skrtic, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688 (2011).
doi: 10.1016/j.ccr.2011.10.015 pubmed: 22094260 pmcid: 3221282
Majetl, R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl Acad. Sci. USA 106, 3396–3401 (2009).
doi: 10.1073/pnas.0900089106
Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
doi: 10.1182/blood-2016-03-643544 pubmed: 27069254
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
doi: 10.1186/gb-2009-10-3-r25 pubmed: 19261174 pmcid: 2690996
Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
doi: 10.1093/bioinformatics/btp120 pubmed: 19289445 pmcid: 2672628
Dunn, J. G. & Weissman, J. S. Plastid: nucleotide-resolution analysis of next-generation sequencing and genomics data. BMC Genomics 17, 958 (2016).
Lauria, F. et al. riboWaltz: optimization of ribosome P-site positioning in ribosome profiling data. PLoS Comput. Biol. 14, e1006169 (2018).
doi: 10.1371/journal.pcbi.1006169 pubmed: 30102689 pmcid: 6112680
Malcovati, L. et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126, 233–241 (2015).
doi: 10.1182/blood-2015-03-633537 pubmed: 25957392 pmcid: 4528082

Auteurs

Nicola Guzzi (N)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Sowndarya Muthukumar (S)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Maciej Cieśla (M)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Gabriele Todisco (G)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Phuong Cao Thi Ngoc (PCT)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Magdalena Madej (M)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Roberto Munita (R)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Serena Fazio (S)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.

Simon Ekström (S)

BioMS-Swedish National Infrastructure for Biological Mass Spectrometry, Lund University, Lund, Sweden.

Teresa Mortera-Blanco (T)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Monika Jansson (M)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan.

Mario Cazzola (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Seishi Ogawa (S)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan.

Luca Malcovati (L)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Eva Hellström-Lindberg (E)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Marios Dimitriou (M)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden. marios.dimitriou@ki.se.

Cristian Bellodi (C)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden. cristian.bellodi@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH